Harvard Bioscience develops, manufactures and sells technologies, products and services that enable fundamental develops in life science applications. Co.'s product families are cellular and molecular technology (CMT) and Preclinical. Co.'s CMT product family includes products supporting research related to molecular, cellular organ and organoid technologies, with additional application in the field of bio-production of pharmaceuticals and therapeutics. Co.'s Preclinical product family includes business lines that support the preclinical research and testing phase for drug development, and in particular testing related to data collection and analysis for safety and regulatory compliance. The HBIO stock yearly return is shown above.
The yearly return on the HBIO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HBIO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|